Entries by Thomas Gabrielczyk

Oxford Science Enterprises raised a further £250 million ($300 million) in funding

Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million (>$1 billion) since inception in 2015 according to the company´s statement.

Swedish Bioinvent issues shares worth SEK299m (USD28m)

BioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including new investors such as AXA Investment Managers and a US institutional investor and the existing shareholders Forbion, HBM Healthcare Investments, Redmile Group, Invus, the Fourth National Swedish Pension Fund and Swedbank Robur Fonder, with demand for the new shares exceeding the size of the planned volume.

Accelerom Automated Sample Preparation Platform

Break free from the long reaction times, high costs, and method complexity of manual proteomic sample preparation with the Thermo Scientific AccelerOme automated sample preparation platform. With factory-supplied reagents and kits, and step-by-step onscreen instructions, high reproducibility and confident results are delivered for both label-free and tandem mass tag (TMT) multiplexing strategies with minimal effort. The AccelerOme platform is optimized to fit into the Thermo Scientific Orbitrap mass spectrometer ecosystem, streamlining the entire workflow from sample preparation to data processing.

Nanobodies: An Important Tool for the Next Generation of Tumor Diagnostics and Therapeutics

Nanobodies are emerging as important tools for tumor diagnosis and treatment due to their small size, simple humanization, low immunogenicity, superior affinity and stability, high penetration, and adequate levels of solubility, and are expected to revolutionize the antibody-based drug therapy. In 2018, the world´s first nanobody was approved for marketing in the European Union to treat adult patients with acquired thrombotic thrombocytopenic purpura. At present, more than 20 nanobodies are being tested in clinical research worldwide, mostly in clinical phase I or II.

Discovering Antigen-specific Monoclonal Antibodies using Single B Cell Screening

Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the Food and Drug Administration (FDA) to treat a variety of diseases ranging from autoimmune disorders, infectious diseases, and cancer [1-2]. In the context of the current COVID-19 pandemic, it´s crucial that these biologics are developed rapidly and efficiently. Among various antibody discovery approaches, including hybridoma technology, single B cell screening is a powerful and efficient strategy for generating antigen-specific mAbs based on the direct amplification of the VH and VL regions encoding genes from single B cells [3-4]. Notably, single B cell screening has various advantages that include maintaining the naïve VH/VL pairing, requiring relatively few cells, and the ability to discover antibodies against challenging targets.

Agomab extenses Series B with USD40m Bringing Total Amount to USD114m

Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million. Pfizer led the extension with an investment through its Pfizer Breakthrough Growth Initiative.